Arthritis Research UK has worked in partnership with the musculoskeletal community, as part of NHS England and the Arthritis and Musculoskeletal Alliance’s (ARMA) Musculoskeletal (MSK) programme, to create the recommended MSK Indicator Set; a standard set of indicators for musculoskeletal health systems relevant to people with MSK conditions and commissioners. The list of indicators and final report are both available to view and download. The Recommended MSK Indicator Set reflects the agreed objectives for musculoskeletal health systems and is a mixture of generic and condition-specific indicators that includes both process and outcome measures. These indicators are intended to be used for local analysis which will highlight the reasons for variation.
Further applications for Clinical pharmacists in the general practice programme have been approved meaning more than 520 clinical pharmacists covering 1,791 GP sites will benefit an additional 18.5 million patients. This builds on the 494 clinical pharmacists already working across around 650 GP practices as part of a pilot scheme. Clinical pharmacists work in general practice teams to help patients manage their medication effectively. This improves the quality of care and ensures patient safety as well as freeing up time for GPs to focus on patients with the most complex health issues. Applications are considered on an on-going basis and the next deadline is 29th September 2017. More information can be found on the NHS England website.
This analysis identifies five key questions to ask each STP area to assess the potential impact of each plan. The scrutiny framework this paper outlines focuses particularly on workforce planning, access to services, service quality, integration of services and numbers of beds.
Health Secretary Jeremy Hunt and NHS England boss Simon Stevens have announced £325m of capital investment for local projects that will help the NHS modernise and transform care for patients.
Hunt and Stevens gave the green light to local capital investment schemes in 15 areas of the country, with the largest sums being used for urgent care in Dorset, surgery in Greater Manchester and cancer care in Cumbria.
Patients will see this investment deliver faster diagnosis for conditions like cancer, easier access to mental health care, expansion of A&Es, shorter waits for operations and more services in GP surgeries.